Brad Loncar's banner

Brad Loncar

@bradloncar • 82,553 subscribers

#Biotech, Founder of @BiotechTV, KC native, @univmiami hurricane.🧬🙌

Videos

Anya Rossi

sweetdream.ai

SweetDream.ai•Sponsored•Livecam

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

Exclusive private shows

1.2k viewers online

Private Show

Join now for exclusive access

Free preview available • Premium content

Think I am likely the last person to have asked Pascal Soriot about M&A. So here it was from June 5th.

Think I am likely the last person to have asked Pascal Soriot about M&A. So here it was from June 5th.

25,934 просмотров • 29 дней назад

𝐎𝐧 𝐂𝐡𝐢𝐧𝐚: Regarding the China debate that has been raging here, a phrase I've heard asked many times is: "What if the next Keytruda comes from China?" Well, this morning I posed this Q to the developer of Keytruda, who has also been in licensing drugs from China lately.

𝐎𝐧 𝐂𝐡𝐢𝐧𝐚: Regarding the China debate that has been raging here, a phrase I've heard asked many times is: "What if the next Keytruda comes from China?" Well, this morning I posed this Q to the developer of Keytruda, who has also been in licensing drugs from China lately.

67,724 просмотров • 3 месяцев назад

My last interview of #ASCO26 - with Celcuity CEO Brian Sullivan. It’s a tough business when your stock trades down 25% after landing a .50 hazard ratio against the standard of care.

My last interview of #ASCO26 - with Celcuity CEO Brian Sullivan. It’s a tough business when your stock trades down 25% after landing a .50 hazard ratio against the standard of care.

34,809 просмотров • 3 месяцев назад

Since Dr. Fauci is in the news, here's a relevant clip from our BiotechTV summit last week (July 21st) where Noubar Afeyan (Moderna Co-Founder) was asked about the job Dr. Fauci did speaking to the nation during covid and thoughts about science communication.

Since Dr. Fauci is in the news, here's a relevant clip from our BiotechTV summit last week (July 21st) where Noubar Afeyan (Moderna Co-Founder) was asked about the job Dr. Fauci did speaking to the nation during covid and thoughts about science communication.

14,583 просмотров • 1 месяц назад

This is a historic data release. A real advance for pancreatic cancer patients, and it shows that our industry goes after the hardest things and can win. #ASCO26

This is a historic data release. A real advance for pancreatic cancer patients, and it shows that our industry goes after the hardest things and can win. #ASCO26

26,052 просмотров • 3 месяцев назад

A couple of weeks ago when I visited Solid Bio, they showed me some videos of Duchenne kids pre and post microdystrophin treatment that I was amazed by - but they weren't sharable yet. Bo just presented them at Needham this week. So cool.

A couple of weeks ago when I visited Solid Bio, they showed me some videos of Duchenne kids pre and post microdystrophin treatment that I was amazed by - but they weren't sharable yet. Bo just presented them at Needham this week. So cool.

23,070 просмотров • 4 месяцев назад

Random example of how cool Cambridge, MA is if you like biotech.

Random example of how cool Cambridge, MA is if you like biotech.

31,591 просмотров • 1 год назад

Gene therapy expert Dr. Nicole Paulk discusses the science of AAV, where it is headed, programs in the pipeline, and how viral vector shortages are causing delays and backlog for clinical trials. What a wealth of info, must watch! #ATW23

Gene therapy expert Dr. Nicole Paulk discusses the science of AAV, where it is headed, programs in the pipeline, and how viral vector shortages are causing delays and backlog for clinical trials. What a wealth of info, must watch! #ATW23

47,547 просмотров • 3 лет назад

This was over two months ago at ASH, so ages, but here's how Disc's CEO said the bitopertin review was going back then. $IRON

This was over two months ago at ASH, so ages, but here's how Disc's CEO said the bitopertin review was going back then. $IRON

12,653 просмотров • 6 месяцев назад

𝐓𝐨𝐧𝐢𝐠𝐡𝐭: Join us in person for the Biotech Hangout BiotechTV hangout from 7:00 to 10:00. All are welcome to attend. Stop by!

𝐓𝐨𝐧𝐢𝐠𝐡𝐭: Join us in person for the Biotech Hangout BiotechTV hangout from 7:00 to 10:00. All are welcome to attend. Stop by!

23,113 просмотров • 1 год назад

With BTK and STAT6 data, this was a big week for degraders. I think Nurix’s Arthur Sands does as good a job as anyone explaining the potential broad utility of this technology.

With BTK and STAT6 data, this was a big week for degraders. I think Nurix’s Arthur Sands does as good a job as anyone explaining the potential broad utility of this technology.

11,283 просмотров • 8 месяцев назад

Thanks for watching BiotechTV’s coverage of Jefferies London these last few days. - Thanks to Amy Brown for hitting it out of the park. - Thanks to Jefferies for hosting us. - And thanks to Stephenson Harwood for sponsoring the coverage. On to Thanksgiving!

Thanks for watching BiotechTV’s coverage of Jefferies London these last few days. - Thanks to Amy Brown for hitting it out of the park. - Thanks to Jefferies for hosting us. - And thanks to Stephenson Harwood for sponsoring the coverage. On to Thanksgiving!

11,688 просмотров • 9 месяцев назад

📽️Caught up with Rachel Haurwitz for the last video of a busy Tuesday. She's had a wild year, I'm impressed with her perseverance. We talk CD19, how data is released at medical meetings, allo vs auto vs bi-specifics, and how she's sticking with her CAR NK (iPSC) program. #JPM23

📽️Caught up with Rachel Haurwitz for the last video of a busy Tuesday. She's had a wild year, I'm impressed with her perseverance. We talk CD19, how data is released at medical meetings, allo vs auto vs bi-specifics, and how she's sticking with her CAR NK (iPSC) program. #JPM23

27,254 просмотров • 3 лет назад

Pascal Touchon has been around cell therapy for a long time, and today he's the first to have an allo T-cell therapy approved. We talk about that, the EBV hypothesis for multiple sclerosis, and cell therapy for solid tumors

Pascal Touchon has been around cell therapy for a long time, and today he's the first to have an allo T-cell therapy approved. We talk about that, the EBV hypothesis for multiple sclerosis, and cell therapy for solid tumors

12,429 просмотров • 3 лет назад

Больше нет контента для загрузки